Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management
Endocrinology · 09.10.2025 · 166 (11)
DOI: 10.1210/endocr/bqaf130 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 16.08.2025. Verfasst von Jiudan Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Growth Differentiation Factor 15, Obesity, Gastric Inhibitory Polypeptide. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 155 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation, Medical and Health Research Project of Zhejiang Province, Zhejiang Province Science and Technology.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The rising global incidence of type 2 diabetes mellitus and obesity underscores a critical public health challenge, with obesity serving as a primary contributor to insulin resistance. Current treatment modalities, including SGLT2 inhibitors and GLP-1 receptor agonists, have shown efficacy in glycemic control and weight management but remain insufficient for all patients. This review focuses on novel dual and triple agonists targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and growth differentiation factor 15 (GDF15) due to their emerging clinical importance and recent preclinical progress. Other peptide-based therapies, such as amylin analogs, are beyond the scope of this work and will be addressed in future reviews. Evidence suggests that these novel agents not only improve metabolic parameters but may also offer cardioprotective and anti-inflammatory benefits. While advancements in understanding their mechanisms of action are promising, the safety profiles of these treatments warrant careful evaluation due to potential adverse effects. This review aims to provide a comprehensive overview of the evolving landscape of antidiabetic pharmacotherapy, emphasizing the unique benefits and challenges of emerging agents to optimize clinical outcomes in type 2 diabetes mellitus management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
- Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin 12203, Germany.
- Hindu Rao Hospital, New Delhi 110007, India.
ORCID-Profile: Jiudan Zhang, Chao Zheng
Förderung
- Zhejiang Provincial Natural Science Foundation
- Medical and Health Research Project of Zhejiang Province
- Zhejiang Province Science and Technology
Zitieren
APA
Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025). Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management. Endocrinology, 166(11). https://doi.org/10.1210/endocr/bqaf130
Vancouver
Zhang J, Sanan S, Csanalosi M, Zheng C, Pfeiffer AFH. Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management. Endocrinology. 2025;166(11). doi:10.1210/endocr/bqaf130
BibTeX
@article{Zhang2025,
author = {Zhang, Jiudan and Sanan, Shriya and Csanalosi, Marta and Zheng, Chao and Pfeiffer, Andreas F H},
title = {Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management},
journal = {Endocrinology},
year = {2025},
volume = {166},
number = {11},
doi = {10.1210/endocr/bqaf130}
}
EUVIMED